Skip to main content
Smart Investors Daily
RG

NASDAQ · RGEN

Repligen Corporation

Healthcare · Medical - Instruments & Supplies

$172.67

Down-$2.38 (-1.38%)

Updated Nov 20, 2026, 1:16 AM

SID Score

5.0/10

Composite research score

Smart Money

58/100

Neutral

Market cap
9.1B
P/E ratio
5,229.48
Dividend yield
0.00%
52-week range
$100.99 – $198.87
Volume
1.3M
Avg. volume
934.31K

Price performance · RGEN

RGEN price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 18, 2026

RGEN closed at $172.67 after 20 trading sessions, down 3.38% for the selected period.

Last close
$172.67
Period change
-3.38%
Period low
$162.18
Period high
$188.64
Daily close
View OHLC price history
RGEN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 18, 2026$163.03$174.435$163.01$172.671.3M
Nov 17, 2026$162.78$165.34$160.27$162.18770.86K
Nov 16, 2026$166.14$166.79$162.48$162.78575.43K
Nov 13, 2026$168.09$169.04$165.26$167.79510.11K
Nov 12, 2026$167.71$169.40$163.85$166.52802.98K
Nov 11, 2026$176.11$178.50$171.99$172.621M
Nov 10, 2026$176.76$178.375$173.85$173.98678.65K
Nov 9, 2026$174.29$181.015$172.39$178.941.1M
Nov 6, 2026$169.35$175.00$168.05$173.491.07M
Nov 5, 2026$175.60$176.655$168.03$168.481.33M
Nov 4, 2026$183.40$188.50$174.39$178.201.06M
Nov 3, 2026$175.54$181.56$173.00$178.271.02M
Nov 2, 2026$178.12$178.12$172.505$172.951.58M
Oct 30, 2026$177.44$180.45$171.23$176.944.47M
Oct 29, 2026$188.42$191.05$185.275$188.64890.27K
Oct 28, 2026$173.54$185.88$173.54$184.691.45M
Oct 27, 2026$168.34$180.00$164.88$175.802.11M
Oct 26, 2026$176.93$181.46$175.80$180.171.18M
Oct 23, 2026$178.30$179.54$174.90$176.931.07M
Oct 22, 2026$179.45$185.025$175.96$178.711.27M

Latest RGEN news

The latest Smart Investors Daily articles mentioning RGEN.

RGEN research

Overview

Company profile and research snapshot.

Company profile

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$171.00
Implied upside
—
Analysts
28
RGEN recent ratings
DateFirmRatingTarget
Oct 28, 2026RBC CapitalOutperform—
Oct 19, 2026Canaccord GenuityHold—
Oct 7, 2026BarclaysOverweight—
Sep 9, 2026UBSBuy—
Jul 30, 2026Wells FargoOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 4, 2026

Repligen Corporation to Present at Jefferies Global Healthcare Conference

WALTHAM, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), today announced that it will participate in the Jefferies Global Healthcare Conference in London, UK. Olivier Loeillot, President and Chief Executive Officer, will participate in an analyst-led discussion on November 18th at 2:00 p.m. GMT. A live webcast of the conference presentation will be accessible through Repligen’s Investor Relations website and will be available for replay for a limited period of time f

Yahoo · Nov 1, 2026

RGEN Q3 deep dive: margin headwinds and BioLife integration shape improved full-year outlook

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported revenue ahead of Wall Street’s expectations in Q3 2026, with sales up 10.9% year on year to $209.3 million. The company’s full-year revenue guidance of $848 million at the midpoint came in 1.3% above analysts’ estimates. Its non-GAAP profit of $0.53 per share was 14.5% above analysts’ consensus estimates.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.